Trevor Pickersgill

Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis

Katharine Harding, Owain Williams, Mark Willis et al. · JAMA Neurology · 2019 · 364 citations · Full text

Medicine, Internal Medicine, Neurology +14

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Anthony G Marson, Girvan Burnside, Richard Appleton et al. · The Lancet · 2021 · 211 citations · Full text

Medicine, Neurology, Pharmacology +17

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Anthony G Marson, Girvan Burnside, Richard Appleton et al. · The Lancet · 2021 · 191 citations · Full text

Medicine, Neurology, Pharmacotherapy +15

Demographic and clinical factors associated with changes in employment in multiple sclerosis

Phil Moore, Katharine Harding, Hannah Clarkson et al. · Multiple Sclerosis Journal · 2013 · 145 citations

Public Health, Neurology, Employment Policy +14

Long-term outcome of paediatric-onset multiple sclerosis: a population-based study

Katharine Harding, Kate Liang, M. Cossburn et al. · Journal of Neurology Neurosurgery & Psychiatry · 2012 · 137 citations

Medicine, Neurology, Pediatrics +14